South Carolina legislature approves $2.4 million for state ADAP

NewsGuard 100/100 Score

South Carolina lawmakers have approved $2.4 million for the state's AIDS Drug Assistance Program, the Columbia State reports (Reid, Columbia State, 5/8). ADAPs are federal- and state-funded programs that provide HIV/AIDS-related medications to low-income, uninsured and underinsured HIV-positive individuals (Kaiser Daily HIV/AIDS Report, 4/9).

The Legislature approved $4 million for the state's ADAP last year, according to the State. South Carolina's contribution has increased from 5% of the program's budget in 2007 to 19% this year. South Carolina ADAP Director Sonya Bayone said that about 100 people in the state apply for ADAP monthly.

"We have finally, as a state, come to grips with HIV/AIDS and are willing to put resources to stem the spread of this disease," Rep. Joe Neal (D), who has led efforts in the state House to allocate money for HIV/AIDS services, said.

According to the State, the new money will help prevent waiting lists, such as the one that increased to 567 people after federal funding for the program was reduced last year. However, the program is expected to face federal funding cuts and increased costs again in the future, the State reports. Higher drug prices, new recommendations that HIV-positive people start treatment earlier and concerted efforts to increase HIV testing have contributed to rising ADAP costs, according to the State.

Helmut Albrecht, chief of Infectious Diseases at the University of South Carolina School of Medicine, said, "This is just bringing us up to where we should be," adding, "In all honesty, we had a lot of catching up to do." Bambi Gaddist, executive director of the South Carolina HIV/AIDS Council, said, "A health agenda is important for economic stability. In the past, we have left HIV off. It's important that we place HIV on that health agenda." About 800 people in South Carolina are diagnosed with HIV/AIDS annually (Columbia State, 5/8).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New drug candidates show promise to reverse HIV immune evasion